Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Grand View Research | PRODUCT CODE: 1869957

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1869957

Antipsychotic Drugs Market Size, Share & Trends Analysis Report By Disease (Schizophrenia, Bipolar Disorder), By Drug, By Therapeutic Class, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033

PUBLISHED:
PAGES: 110 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Antipsychotic Drugs Market Summary

The global antipsychotic drugs market size was estimated at USD 17.53 billion in 2024 and is projected to reach USD 32.24 billion by 2033, growing at a CAGR of 6.1% from 2025 to 2033. The market is expanding due to the increasing prevalence of mental health disorders, greater awareness, and innovations. Government support, insurance coverage, and the availability of generics are further driving accessibility, especially in emerging markets.

Antipsychotic medications, also known as neuroleptics, are commonly employed to alleviate symptoms linked to psychosis. Antipsychotic medications can effectively decrease and manage various symptoms, such as paranoia and auditory hallucinations, including delusions and hearing voices. Antipsychotic medications work by inhibiting the activity of dopamine and other neurotransmitters in the brain. First and second-generation antipsychotic medications are currently available in the market.

The increasing prevalence of psychotic disorders is expected to drive the demand in the antipsychotic drugs industry. The Schizophrenia burden consistently affects men more than women, and as life expectancy improves regionally, the overall burden of Schizophrenia is expected to grow further. Aging populations also support demand, as conditions such as dementia-related psychosis become more prevalent. Market growth has been reinforced by regulatory approvals of new formulations and novel mechanisms of action, which address limitations of older therapies.

Advancements in technology and research in drug development have also resulted in the creation of newer and more efficient Antipsychotic drugs. Pharmaceutical companies are investing significantly in researching and developing medications with fewer side effects, higher effectiveness, and enhanced patient adherence. In September 2025, H. Lundbeck A/S and Otsuka Holdings Co., Ltd received a Complete Response Letter (CRL) from the FDA for a supplemental New Drug Application (NDA) for REXULTI (brexpiprazole) in combination with sertraline for treating adults with PTSD.

In January 2023, Eisai Co., Ltd. obtained FDA approval for Leqembi through the Accelerated Approval Pathway for Alzheimer's disease treatment. The introduction of advanced pharmaceutical choices for neurological disorders is increasing the use of antipsychotic drugs among patients worldwide.

Global Antipsychotic Drugs Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antipsychotic drugs market report based on disease, drug, therapeutic class, distribution channel, and region:

  • Disease Outlook (Revenue, USD Million, 2021 - 2033)
  • Schizophrenia
  • Bipolar Disorder
  • Unipolar Depression
  • Dementia
  • Others
  • Drug Outlook (Revenue, USD Million, 2021 - 2033)
  • Risperidone
  • Quetiapine
  • Olanzapine
  • Aripiprazole
  • Brexpiprazole
  • Paliperidone Palmitate
  • Others
  • Therapeutic Class Outlook (Revenue, USD Million, 2021 - 2033)
  • First Generation
  • Second Generation
  • Third Generation
  • Distribution Channel Class Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
Product Code: GVR-1-68038-408-6

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Drug
    • 1.2.3. Therapeutic class
    • 1.2.4. Distribution channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease outlook
    • 2.2.2. Drug outlook
    • 2.2.3. Therapeutic class
    • 2.2.4. Distribution Channel
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Antipsychotic Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Antipsychotic Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Antipsychotic Drugs Market: Disease Estimates & Trend Analysis

  • 4.1. Disease Segment Dashboard
  • 4.2. Antipsychotic Drugs Market: Disease Movement Analysis
  • 4.3. Global Antipsychotic Drugs Market Size & Trend Analysis, by Disease, 2021 to 2033 (USD Million)
    • 4.3.1. Schizophrenia
      • 4.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.2. Bipolar Disorder
      • 4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.3. Unipolar Depression
      • 4.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.4. Dementia
      • 4.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.5. Others
      • 4.3.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Antipsychotic Drugs Market: Drugs Estimates & Trend Analysis

  • 5.1. Drugs Segment Dashboard
  • 5.2. Antipsychotic Drugs Market: Drug Movement Analysis
  • 5.3. Global Antipsychotic Drugs Market Size & Trend Analysis, by Drugs, 2021 to 2033 (USD Million)
    • 5.3.1. Risperidone
      • 5.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.2. Quetiapine
      • 5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.3. Olanzapine
      • 5.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.4. Aripiprazole
      • 5.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.5. Brexpiprazole
      • 5.3.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.6. Paliperidone Palmitate
      • 5.3.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.7. Others
      • 5.3.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Antipsychotic Drugs Market: Therapeutic Class Estimates & Trend Analysis

  • 6.1. Therapeutic Class Segment Dashboard
  • 6.2. Antipsychotic Drugs Market: Therapeutic Class Movement Analysis
  • 6.3. Global Antipsychotic Drugs Market Size & Trend Analysis, by Therapeutic Class, 2021 to 2033 (USD Million)
    • 6.3.1. First Generation
      • 6.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.3.2. Second Generation
      • 6.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.3.3. Third Generation
      • 6.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Antipsychotic Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Distribution Channel Segment Dashboard
  • 7.2. Antipsychotic Drugs Market: Distribution Channel Movement Analysis
  • 7.3. Global Antipsychotic Drugs Market Size & Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
    • 7.3.1. Hospital Pharmacies
      • 7.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.2. Retail Pharmacies
      • 7.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.3. Online Pharmacies
      • 7.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Antipsychotic Drugs Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Dashboard
  • 8.2. Regional Market Share Analysis, 2024 & 2033
  • 8.3. Continuous bioprocessing market by Region: Key Takeaways
  • 8.4. North America
    • 8.4.1. U.S.
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.2. Canada
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.3. Mexico
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. UK
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.2. Germany
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.3. France
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.4. Italy
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.5. Spain
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.6. Denmark
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.7. Sweden
      • 8.5.7.1. Key country dynamics
      • 8.5.7.2. Regulatory framework/ reimbursement structure
      • 8.5.7.3. Competitive scenario
      • 8.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.8. Norway
      • 8.5.8.1. Key country dynamics
      • 8.5.8.2. Regulatory framework/ reimbursement structure
      • 8.5.8.3. Competitive scenario
      • 8.5.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Japan
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.2. China
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.3. India
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.4. Australia
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.6. Thailand
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Brazil
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.2. Argentina
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8. MEA
    • 8.8.1. South Africa
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.2. Saudi Arabia
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.3. UAE
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/ reimbursement structure
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.4. Kuwait
      • 8.8.4.1. Key country dynamics
      • 8.8.4.2. Regulatory framework/ reimbursement structure
      • 8.8.4.3. Competitive scenario
      • 8.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. Key company heat map analysis, 2024
  • 9.4. Company Profiles
    • 9.4.1. H. Lundbeck A/S
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Otsuka Pharmaceutical Co., Ltd.
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Janssen Pharmaceuticals, Inc.
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Eli Lilly and Company
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. AbbVie, Inc.
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Teva Pharmaceutical Industries Ltd.
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Dr Reddy's Laboratories Ltd.
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. Sumitomo Pharma Co., Ltd.
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Alkermes
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. Bristol-Myers Squibb Company
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives
Product Code: GVR-1-68038-408-6

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global antipsychotic drugs market, by region, 2021 - 2033 (USD Million)
  • Table 3 Global antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 4 Global antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 5 Global antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 6 Global antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 7 North America antipsychotic drugs market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 9 North America antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 10 North America antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 11 North America antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 12 U.S. antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 13 U.S. antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 14 U.S. antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 15 U.S. antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 16 Canada antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 17 Canada antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 18 Canada antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 19 Mexico antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 20 Mexico antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 21 Mexico surgical ablation market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 22 Mexico antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 23 Europe antipsychotic drugs market, by country, 2021 - 2033 (USD Million)
  • Table 24 Europe antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 25 Europe antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 26 Europe antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 27 Europe antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28 UK antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 29 UK antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 30 UK antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 31 UK antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 32 Germany antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 33 Germany antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 34 Germany antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 35 Germany antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 36 France antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 37 France antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 38 France antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 39 France antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 40 Italy antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 41 Italy antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 42 Italy antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 43 Italy antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 44 Spain antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 45 Spain antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 46 Spain antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 47 Spain antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 48 Denmark antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 49 Denmark antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 50 Denmark antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 51 Denmark antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Sweden antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 53 Sweden antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 54 Sweden antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 55 Sweden antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56 Norway antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 57 Norway antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 58 Norway antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 59 Norway antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 60 Asia Pacific antipsychotic drugs market, by country, 2021 - 2033 (USD Million)
  • Table 61 Asia Pacific antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65 Japan antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 66 Japan antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 67 Japan antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 68 Japan antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 69 China antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 70 China antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 71 China antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 72 China antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 73 India antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 74 India antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 75 India antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 76 India antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 77 Australia antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 78 Australia antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 79 Australia antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 80 Australia antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 81 South Korea antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 82 South Korea antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 83 South Korea antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 84 South Korea antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 85 Thailand antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 86 Thailand antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 87 Thailand antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 88 Thailand antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 89 Latin America antipsychotic drugs market, by country, 2021 - 2033 (USD Million)
  • Table 90 Latin America antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 91 Latin America surgical ablation market, by drug, 2021 - 2033 (USD Million)
  • Table 92 Latin America laparoscopic ablation market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 93 Latin America percutaneous ablation market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 94 Brazil Antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 95 Brazil Antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 96 Brazil surgical ablation market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 97 Brazil antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 98 Argentina Antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 99 Argentina Antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 100 Argentina surgical ablation market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 101 Argentina antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 102 MEA Antipsychotic drugs market, by region, 2021 - 2033 (USD Million)
  • Table 103 MEA Antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 104 MEA Antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 105 MEA Antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 106 MEA antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 107 South Africa Antipsychotic drugs market, by Disease, 2021 - 2033 (USD Million)
  • Table 108 South Africa Antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 109 South Africa Antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 110 South Africa antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 111 Saudi Arabia Antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 112 Saudi Arabia Antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia Antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 115 UAE Antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 116 UAE Antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 117 UAE Antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 118 UAE antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 119 Kuwait Antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 120 Kuwait Antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 121 Kuwait Antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 122 Kuwait antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Antipsychotic drugs market: market outlook
  • Fig. 10 Antipsychotic drugs: Competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Antipsychotic drugs market driver impact
  • Fig. 16 Antipsychotic drugs market restraint impact
  • Fig. 17 Antipsychotic drugs market strategic initiatives analysis
  • Fig. 18 Antipsychotic drugs market: disease movement analysis
  • Fig. 19 Antipsychotic drugs market: disease outlook and key takeaways
  • Fig. 20 Schizophrenia market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 21 Bipolar disorder market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Unipolar depression market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Dementia market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 Other market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Antipsychotic drugs market: Drug movement Analysis
  • Fig. 26 Antipsychotic drugs market: Drug outlook and key takeaways
  • Fig. 27 Schizophrenia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Bipolar disorder market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 29 Unipolar depression market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 30 Dementia market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 31 Other market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 32 Antipsychotic drugs market: Therapeutic class movement analysis
  • Fig. 33 Antipsychotic drugs market: Therapeutic Class outlook and key takeaways
  • Fig. 34 First-generation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Second-generation market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 36 Third-generation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Antipsychotic drugs market: Distribution channel movement analysis
  • Fig. 38 Antipsychotic drugs market: Distribution channel outlook and key takeaways
  • Fig. 39 Hospital pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Retail pharmacies market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 41 Online pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Global antipsychotic drugs market: Regional movement analysis
  • Fig. 43 Global antipsychotic drugs market: Regional outlook and key takeaways
  • Fig. 44 North America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Europe market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 France market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 China market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 India market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Middle East and Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!